395 related articles for article (PubMed ID: 20884712)
1. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Hose D; Rème T; Meissner T; Moreaux J; Seckinger A; Lewis J; Benes V; Benner A; Hundemer M; Hielscher T; Shaughnessy JD; Barlogie B; Neben K; Krämer A; Hillengass J; Bertsch U; Jauch A; De Vos J; Rossi JF; Möhler T; Blake J; Zimmermann J; Klein B; Goldschmidt H
Blood; 2009 Apr; 113(18):4331-40. PubMed ID: 19171872
[TBL] [Abstract][Full Text] [Related]
3. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
5. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler GM; Benner A; Hundemer M; Rème T; Shaughnessy JD; Barlogie B; Bertsch U; Hillengass J; Ho AD; Pantesco V; Jauch A; De Vos J; Rossi JF; Möhler T; Klein B; Hose D
Oncogene; 2009 Nov; 28(44):3866-79. PubMed ID: 19718049
[TBL] [Abstract][Full Text] [Related]
7. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
8. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
9. Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic role of annexin A2 in multiple myeloma.
Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D
Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
13. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
Zojer N; Königsberg R; Ackermann J; Fritz E; Dallinger S; Krömer E; Kaufmann H; Riedl L; Gisslinger H; Schreiber S; Heinz R; Ludwig H; Huber H; Drach J
Blood; 2000 Mar; 95(6):1925-30. PubMed ID: 10706856
[TBL] [Abstract][Full Text] [Related]
14. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
15. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in multiple myeloma.
Rajkumar SV; Greipp PR
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1295-314, xi. PubMed ID: 10626152
[TBL] [Abstract][Full Text] [Related]
17. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.
Seckinger A; Meißner T; Moreaux J; Benes V; Hillengass J; Castoldi M; Zimmermann J; Ho AD; Jauch A; Goldschmidt H; Klein B; Hose D
Oncotarget; 2015 Nov; 6(36):39165-83. PubMed ID: 26472281
[TBL] [Abstract][Full Text] [Related]
18. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
19. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
[TBL] [Abstract][Full Text] [Related]
20. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
